Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 46% ± 14% | |
lung | 19 studies | 51% ± 16% | |
brain | 18 studies | 35% ± 15% | |
intestine | 12 studies | 33% ± 16% | |
eye | 12 studies | 59% ± 25% | |
kidney | 9 studies | 48% ± 15% | |
lymph node | 7 studies | 48% ± 19% | |
bone marrow | 6 studies | 39% ± 13% | |
prostate | 5 studies | 44% ± 17% | |
liver | 5 studies | 24% ± 6% | |
pancreas | 4 studies | 58% ± 33% | |
placenta | 4 studies | 66% ± 28% | |
heart | 4 studies | 27% ± 9% | |
uterus | 4 studies | 48% ± 19% | |
esophagus | 4 studies | 46% ± 27% | |
breast | 4 studies | 42% ± 7% | |
adrenal gland | 3 studies | 44% ± 7% | |
skin | 3 studies | 42% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 46457.53 | 1445 / 1445 | 100% | 599.47 | 183 / 183 |
skin | 100% | 59812.03 | 1807 / 1809 | 100% | 845.17 | 472 / 472 |
kidney | 100% | 43879.54 | 89 / 89 | 100% | 776.01 | 900 / 901 |
brain | 100% | 46568.24 | 2632 / 2642 | 100% | 461.86 | 705 / 705 |
ovary | 99% | 18404.39 | 179 / 180 | 100% | 651.49 | 430 / 430 |
intestine | 100% | 23504.95 | 965 / 966 | 99% | 500.95 | 521 / 527 |
uterus | 99% | 21428.31 | 168 / 170 | 100% | 758.92 | 458 / 459 |
lung | 99% | 29245.66 | 574 / 578 | 99% | 628.71 | 1144 / 1155 |
bladder | 100% | 36865.38 | 21 / 21 | 98% | 632.01 | 494 / 504 |
thymus | 99% | 22051.38 | 647 / 653 | 98% | 331.95 | 595 / 605 |
prostate | 100% | 31412.20 | 245 / 245 | 97% | 260.40 | 489 / 502 |
stomach | 99% | 20234.50 | 354 / 359 | 99% | 407.30 | 282 / 286 |
breast | 98% | 23111.05 | 450 / 459 | 99% | 457.19 | 1104 / 1118 |
adrenal gland | 100% | 65345.17 | 258 / 258 | 96% | 386.83 | 220 / 230 |
pancreas | 35% | 4057.54 | 114 / 328 | 98% | 565.90 | 174 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 799.54 | 29 / 29 |
muscle | 100% | 92030.24 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 27528.54 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 792.14 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 317.93 | 1 / 1 |
blood vessel | 100% | 40999.31 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 68878.92 | 918 / 929 | 0% | 0 | 0 / 0 |
adipose | 98% | 20857.35 | 1175 / 1204 | 0% | 0 | 0 / 0 |
heart | 97% | 49628.22 | 832 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 306.11 | 76 / 80 |
liver | 4% | 541.16 | 8 / 226 | 21% | 86.93 | 86 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000767 | Biological process | positive regulation of cytoplasmic translation |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0012501 | Biological process | programmed cell death |
GO_0006096 | Biological process | glycolytic process |
GO_1903672 | Biological process | positive regulation of sprouting angiogenesis |
GO_0061621 | Biological process | canonical glycolysis |
GO_0005576 | Cellular component | extracellular region |
GO_0005739 | Cellular component | mitochondrion |
GO_0070062 | Cellular component | extracellular exosome |
GO_1903561 | Cellular component | extracellular vesicle |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0034774 | Cellular component | secretory granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0005929 | Cellular component | cilium |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005791 | Cellular component | rough endoplasmic reticulum |
GO_0031982 | Cellular component | vesicle |
GO_0005634 | Cellular component | nucleus |
GO_0004743 | Molecular function | pyruvate kinase activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0030955 | Molecular function | potassium ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0023026 | Molecular function | MHC class II protein complex binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PKM |
Protein name | Pyruvate kinase M1/2 pyruvate kinase (EC 2.7.1.40) Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Threonine-protein kinase PKM2) (EC 2.7.11.1) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (Tyrosine-protein kinase PKM2) (EC 2.7.10.2) (p58) Pyruvate kinase (EC 2.7.1.40) |
Synonyms | PK3 PK2 OIP3 PKM2 hCG_2005199 |
Description | FUNCTION: Catalyzes the final rate-limiting step of glycolysis by mediating the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP . The ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production . The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival . .; FUNCTION: [Isoform M2]: Isoform specifically expressed during embryogenesis that has low pyruvate kinase activity by itself and requires allosteric activation by D-fructose 1,6-bisphosphate (FBP) for pyruvate kinase activity . In addition to its pyruvate kinase activity in the cytoplasm, also acts as a regulator of transcription in the nucleus by acting as a protein kinase . Translocates into the nucleus in response to various signals, such as EGF receptor activation, and homodimerizes, leading to its conversion into a protein threonine- and tyrosine-protein kinase . Catalyzes phosphorylation of STAT3 at 'Tyr-705' and histone H3 at 'Thr-11' (H3T11ph), leading to activate transcription . Its ability to activate transcription plays a role in cancer cells by promoting cell proliferation and promote tumorigenesis . Promotes the expression of the immune checkpoint protein CD274 in BMAL1-deficient macrophages (By similarity). May also act as a translation regulator for a subset of mRNAs, independently of its pyruvate kinase activity: associates with subpools of endoplasmic reticulum-associated ribosomes, binds directly to the mRNAs translated at the endoplasmic reticulum and promotes translation of these endoplasmic reticulum-destined mRNAs (By similarity). Plays a role in caspase independent cell death of tumor cells . .; FUNCTION: [Isoform M1]: Pyruvate kinase isoform expressed in adult tissues, which replaces isoform M2 after birth . In contrast to isoform M2, has high pyruvate kinase activity by itself and does not require allosteric activation by D-fructose 1,6-bisphosphate (FBP) for activity . . |
Accessions | ENST00000698740.1 ENST00000565154.6 ENST00000562997.5 H3BTN5 P14618 ENST00000335181.10 [P14618-1] ENST00000567087.5 ENST00000698741.1 ENST00000569857.5 ENST00000568459.5 [P14618-2] H3BUW1 ENST00000561609.5 A0A804F729 A0A8V8TNX9 H3BQZ3 ENST00000566809.1 ENST00000564178.5 A0A8V8TMM5 ENST00000569050.1 H3BTJ2 H3BT25 ENST00000567118.5 ENST00000319622.10 [P14618-2] H3BU13 B4DNK4 H3BN34 A0A804F6T5 ENST00000565184.6 ENST00000389093.7 H3BQ34 |